NO20055143L - Doseringsformer innbefattende AG013736 - Google Patents

Doseringsformer innbefattende AG013736

Info

Publication number
NO20055143L
NO20055143L NO20055143A NO20055143A NO20055143L NO 20055143 L NO20055143 L NO 20055143L NO 20055143 A NO20055143 A NO 20055143A NO 20055143 A NO20055143 A NO 20055143A NO 20055143 L NO20055143 L NO 20055143L
Authority
NO
Norway
Prior art keywords
dosage forms
forms including
prodrugs
solvates
cancers
Prior art date
Application number
NO20055143A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055143D0 (no
Inventor
James Lawrence Freddo
Dana Hu-Lowe
Yazdi Kersi Pithavala
Heidi Marie Steinfeldt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20055143D0 publication Critical patent/NO20055143D0/no
Publication of NO20055143L publication Critical patent/NO20055143L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20055143A 2003-04-03 2005-11-02 Doseringsformer innbefattende AG013736 NO20055143L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31
PCT/IB2004/000867 WO2004087152A1 (fr) 2003-04-03 2004-03-17 Formes posologiques renfermant ag013736

Publications (2)

Publication Number Publication Date
NO20055143D0 NO20055143D0 (no) 2005-11-02
NO20055143L true NO20055143L (no) 2006-01-03

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055143A NO20055143L (no) 2003-04-03 2005-11-02 Doseringsformer innbefattende AG013736

Country Status (16)

Country Link
US (1) US20040224988A1 (fr)
EP (1) EP1613320A1 (fr)
JP (1) JP2006522087A (fr)
KR (1) KR20050119671A (fr)
AR (1) AR043822A1 (fr)
AU (1) AU2004226586B2 (fr)
BR (1) BRPI0409230A (fr)
CA (1) CA2520932A1 (fr)
MX (1) MXPA05009303A (fr)
NL (1) NL1025873C2 (fr)
NO (1) NO20055143L (fr)
PA (1) PA8599701A1 (fr)
RU (2) RU2341263C2 (fr)
TW (1) TW200423933A (fr)
UY (1) UY28255A1 (fr)
WO (1) WO2004087152A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2561516A1 (fr) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinaisons d'inhibiteurs de transduction de signaux
CA2586174A1 (fr) * 2004-11-02 2006-05-11 Brigitte Leigh Ewanicki Methodes de preparation de composes d'indazole
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CN103626739B (zh) 2007-04-05 2015-12-30 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-(甲基-氨甲酰基)苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
EP3124046B1 (fr) 2007-07-12 2019-12-25 GITR, Inc. Thérapies combinées utilisant des molécules de liaison gitr
EP2294184A4 (fr) 2008-06-30 2013-03-06 Mesoblast Inc Traitement de maladies oculaires et d une néovascularisation excessive utilisant un traitement combiné
EP2760434A1 (fr) 2011-09-30 2014-08-06 Pfizer Inc Compositions pharmaceutiques de n-méthyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl-benzamide
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
HUE057205T2 (hu) * 2014-02-04 2022-04-28 Pfizer PD-1 antagonista és VEGFR inhibitor kombinációja rák kezelésére
JP6414727B2 (ja) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 関節疾患の治療予防剤
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
CA2955676A1 (fr) 2014-08-25 2016-03-03 Pfizer Inc. Combinaison d'un antagoniste de pd-1 et d'un inhibiteur d'alk dans le traitement du cancer
JP6885869B2 (ja) 2015-02-26 2021-06-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ がんを治療するためのｐｄ−１／ｐｄ−ｌ１阻害剤
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
JP2019508405A (ja) 2016-02-08 2019-03-28 ヴィトリサ セラピューティクス， インコーポレイテッド 改良された硝子体内半減期を有する組成物およびその使用
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
WO2020128893A1 (fr) 2018-12-21 2020-06-25 Pfizer Inc. Traitements combinés de cancer comprenant un agoniste de tlr
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE503496T1 (de) * 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ATE198326T1 (de) * 1995-04-20 2001-01-15 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (ja) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 光パワー計測システム並びにそのための端局及び中継器
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
EP1613320A1 (fr) 2006-01-11
RU2005128791A (ru) 2006-05-10
CA2520932A1 (fr) 2004-10-14
AR043822A1 (es) 2005-08-17
NL1025873C2 (nl) 2006-02-14
AU2004226586B2 (en) 2008-12-11
AU2004226586A1 (en) 2004-10-14
PA8599701A1 (es) 2004-11-26
BRPI0409230A (pt) 2006-03-28
US20040224988A1 (en) 2004-11-11
RU2341263C2 (ru) 2008-12-20
UY28255A1 (es) 2004-11-30
KR20050119671A (ko) 2005-12-21
RU2008122358A (ru) 2009-12-10
NO20055143D0 (no) 2005-11-02
WO2004087152A1 (fr) 2004-10-14
JP2006522087A (ja) 2006-09-28
TW200423933A (en) 2004-11-16
MXPA05009303A (es) 2005-10-05
NL1025873A1 (nl) 2004-10-05

Similar Documents

Publication Publication Date Title
NO20055143L (no) Doseringsformer innbefattende AG013736
NO20051303L (no) Nye benzoimidazolderivater nyttige som antiproliferative midler
NO20053483L (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
WO2008012635A3 (fr) Dérivés d'amines utiles en tant qu'agents anticancéreux
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20062691L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20063382L (no) Nye kinolinderivater
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
ECSP055867A (es) Derivados de pirrolopirimidina
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
WO2006067614A3 (fr) Derives heteroaromatiques utiles en tant qu'agents anticancereux
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
EA200701745A1 (ru) Циклопропанкарбоксамидные производные
NO20050921L (no) Nye fysiologisk aktive substanser
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
NO20076254L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application